10,410 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Bought by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. bought a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 10,410 shares of the company’s stock, valued at approximately $32,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Stifel Financial Corp increased its holdings in TScan Therapeutics by 3.9% during the third quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock worth $494,000 after buying an additional 3,733 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of TScan Therapeutics by 31.2% in the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock valued at $62,000 after purchasing an additional 4,852 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of TScan Therapeutics in the second quarter valued at $70,000. MetLife Investment Management LLC increased its holdings in shares of TScan Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock valued at $116,000 after purchasing an additional 13,164 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of TScan Therapeutics in the second quarter valued at $90,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock opened at $2.43 on Wednesday. The firm has a 50-day moving average of $3.12 and a 200-day moving average of $4.69. The stock has a market cap of $129.69 million, a PE ratio of -2.29 and a beta of 0.88. TScan Therapeutics, Inc. has a 52-week low of $2.31 and a 52-week high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, sell-side analysts forecast that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

Wall Street Analyst Weigh In

TCRX has been the topic of several research reports. Wedbush reiterated an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Monday, December 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.